|
1
|
Thomas DA: Philadelphia chromosome
positive acute lymphocytic leukemia: A new era of challenges.
Hematology Am Soc Hematol Educ Program. 435–443. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mishra S, Zhang B, Cunnick JM, Heisterkamp
N and Groffen J: Resistance to imatinib of bcr/abl p190
lymphoblastic leukemia cells. Cancer Res. 66:5387–5393. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cilloni D and Saglio G: Molecular
pathways: BCR-ABL. Clin Cancer Res. 18:930–937. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hoffman A and Baltimore D: Circuitry of
nuclear factor kappaB signaling. Immunol Rev. 210:171–186. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mishra S, Pertz V, Zhang B, Kaur P,
Shimada H, Groffen J, Kazimierczuk Z, Pinna LA and Heisterkamp N:
Treatment of P190 Bcr/Abl lymphoblastic leukemia cells with
inhibitors of the serine/threonine kinase CK2. Leukemia.
21:178–180. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Morotti A, Carrà G, Panuzzo C, Crivellaro
S, Taulli R, Guerrasio A and Saglio G: Protein kinase CK2: A
targetable BCR-ABL partner in philadelphia positive leukemias. Adv
Hematol. 2015:6125672015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fielding AK: How I treat Philadelphia
chromosome-positive acute lymphoblastic leukemia. Blood.
116:3409–3417. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Thomas DA, Sarris AH, Cortes J, Faderl S,
O'Brien S, Giles FJ, Garcia-Manero G, Rodrigues MA, Cabanillas F
and Cantarjian H: Phase II study of sphingosomal vincristine in
patients with recurrent or refractory adult acute lymphocytic
leukemia. Cancer. 106:120–127. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Stock W, Johnson J, Yu D, Bennett D, Sher
D, Stone R, Kolitz J, Powell B, Wetzler M, Vardiman J, et al:
Daunorubicin dose intensification during treatment of adult acute
lymphoblastic leukemia (ALL): Final results from cancer and
leukemia group B study 19802. Blood. 106:18332005.
|
|
10
|
Lyseng-Williamson K and Jarvis B:
Imatinib. Drugs. 61:1765–1776. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Soverini I, De Benedittis C, Papayannidis
C, Paolini S, Venturi C, Iacobucci I, Luppi M, Bresciani P,
Salvucci M, Russo D, et al: Drug resistance and BCR-ABL kinase
domain mutations in Philadelphia chromosome-positive acute
lymphoblastic leukemia from the imatinib to the second-generation
tyrosine kinase inhibitor era: The main changes are in the type of
mutations, but not in the frequency of mutation involvement.
Cancer. 120:1002–1009. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chattopadhyay I, Biswas K, Bandyopadhyay U
and Banerjee RK: Turmeric and curcumin Biological actions and
medicinal applications. Curr Sci. 87:44–50. 2004.
|
|
13
|
Ravindran J, Prasad S and Aggarwal BB:
Curcumin and cancer cells: How many ways can curry kill tumor cells
selectively? AAPS J. 11:495–510. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kunnumakkara AB, Anand P and Aggarwal BB:
Curcumin inhibits proliferation, invasion, angiogenesis and
metastasis of different cancers through interaction with multiple
cell signaling proteins. Cancer Lett. 269:199–225. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kunwar A, Barik A, Mishra B, Rathinasamy
K, Pandey R and Priyadarsini K: Quantitative cellular uptake,
localization and cytotoxicity of curcumin in normal and tumor
cells. Biochim Biophys Acta. 1780:673–679. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF,
Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, et al: Phase I
clinical trial of curcumin, a chemopreventive agent, in patients
with high-risk or pre-malignant lesions. Anticancer Res.
21:2895–2900. 2001.PubMed/NCBI
|
|
17
|
Singh S and Aggarwal BB: Activation of
transcription factor NF-kappa B is suppressed by curcumin
(diferuloylmethane) [corrected]. J Biol Chem. 270:24995–25000.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zeligs KP, Neuman MK and Annunziata CM:
Molecular pathways: The balance between cancer and the immune
system challenges the therapeutic specificity of targeting nuclear
factor-κB signaling for cancer treatment. Clin Cancer Res.
22:4302–4308. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xia Y, Shen S and Verma I: NF-κB, an
active player in human cancers. Cancer Immunol Res. 2:823–830.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak K and Schmittgen T: Analysis of
relative gene expression data using realtime quantitative PCR and
the 2(Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chou TC: Theoretical basis, experimental
design, and computerized simulation of synergism and antagonism in
drug combination studies. Pharmacol Rev. 68:621–681. 2006.
View Article : Google Scholar
|
|
22
|
Chou J and Chou TC: Computerized
simulation of dose reduction index (DRI) in synergistic drug
combinations. Pharmacologist. 30:A2311988.
|
|
23
|
Rahmani AH, Al Zohairy MA, Aly SM and Khan
MA: Curcumin: A potential candidate in prevention of cancer via
modulation of molecular pathways. Biomed Res Int. 2014:7616082014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen J, Wang FL and Chen WD: Modulation of
apoptosis-related cell signaling pathways by curcumin as a strategy
to inhibit tumor progression. Mol Biol Rep. 41:4583–4594. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Guo Y, Li Y, Shan Q, He G, Lin J and Gong
Y: Curcumin potentiates the anti-leukemia effects of imatinib by
downregulation of the AKT/mTOR pathway and BCR/ABL gene expression
in Ph+ acute lymphoblastic leukemia. Int J Biochem Cell Biol.
65:1–11. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gupta M, Kumar A and Dabadghao S:
Resistance of bcr-abl-positive acute lymphoblastic leukemia to
daunorubicin is not mediated by mdr1 gene expression. Am J Hematol.
71:172–176. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kang MH, Kang YH, Szymanska B,
Wilczynska-Kalak U, Sheard MA, Harned TM, Lock RB and Reynolds CP:
Activity of vincristine, L-ASP, and dexamethasone against acute
lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in
vitro and in vivo. Blood. 110:2057–2066. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pimentel-Gutiérrez HJ, Bobadilla-Morales
L, Barba-Barba CC, Ortega-De-La-Torre C, Sánchez-Zubieta FA,
Corona-Rivera JR, González-Quezada BA, Armendáriz-Borunda JS,
Silva-Cruz R and Corona-Rivera A: Curcumin potentiates the effect
of chemotherapy against acute lymphoblastic leukemia cells via
downregulation of NF-κB. Oncol Lett. 12:4117–4124. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang J, Wang F, Li F, Zhang W, Shen Y,
Zhou D and Guo S: A multifunctional poly(curcumin) nanomedicine for
dual-modal targeted delivery, intracellular responsive release,
dual-drug treatment and imaging of multidrug resistant cancer
cells. J Mater Chem B. 4:2954–2962. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Langevin PB and Atlee JL: Chemotherapeutic
agents. Complications Anesth. 2:110–118. 2007. View Article : Google Scholar
|
|
31
|
Das K and White C: Activation of NF-kappaB
by antineoplastic agents. Role of protein kinase C. J Biol Chem.
272:14914–14920. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Demiray M, Sahinbas H, Atahan S, Demiray
H, Selcuk D, Yildirim I and Atayoglu A: Successful treatment of
c-kit-positive metastatic adenoid cystic carcinoma (ACC) with a
combination of curcumin plus imatinib: A case report. Complement
Ther Med. 27:108–113. 2016. View Article : Google Scholar : PubMed/NCBI
|
